Cargando…
Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma
Supplemental Digital Content is available in the text
Autores principales: | Deshantri, Anil K., Fens, Marcel H.A.M., Ruiter, Ruud W.J., Metselaar, Josbert M., Storm, Gert, Mandhane, Sanjay N., Graat, Gerard H.M., Lentjes, Eef G.W., Yuan, Huipin, de Bruijn, Joost D., Mutis, Tuna, Martens, Anton C.M., Groen, Richard W.J., Schiffelers, Raymond M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455224/ https://www.ncbi.nlm.nih.gov/pubmed/32923984 http://dx.doi.org/10.1097/HS9.0000000000000463 |
Ejemplares similares
-
Development and characterization of liposomal formulation of bortezomib
por: Deshantri, Anil K., et al.
Publicado: (2019) -
Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model
por: Varela-Moreira, Aida, et al.
Publicado: (2020) -
Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
por: Braham, Maaike VJ, et al.
Publicado: (2018) -
Changes in circulating endothelial progenitor cells predict responses of
multiple myeloma patients to treatment with bortezomib and
dexamethasone
por: Wang, L., et al.
Publicado: (2015) -
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
por: Stikvoort, Arwen, et al.
Publicado: (2021)